查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591850

組蛋白去乙醯化酶抑制劑市場：按類別、應用分類 - 2025-2030 年全球預測

Histone Deacetylase Inhibitors Market by Class (Class I HDACs, Class II HDACs, Class III HDACs), Application (Central Nervous System Disorders, Neurology, Oncology) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年組蛋白去乙醯化酶抑制劑市值為164.3億美元，預計2024年將達到183.2億美元，複合年成長率為11.96%，到2030年將達到362億美元，預計將達到5,000萬美元。

組蛋白去乙醯化酶抑制劑（HDAC 抑制劑）是一類抑制組蛋白去乙醯化酶功能的化合物，組蛋白去乙醯化酶是一種參與修飾染色質結構和控制基因表現的酵素。 HDAC 抑制劑的主要用途是在腫瘤學中，利用其誘導癌細胞凋亡和細胞週期停滯的能力。然而，由於其在表觀遺傳調控中的作用，其應用範圍也擴展到神經和發炎疾病。一系列最終用途包括主要專注於新型癌症治療的製藥公司，以及尋求阿茲海默症和亨廷頓治療方法的研究人員。 HDAC 抑制劑市場的成長主要受到癌症和神經退化性疾病盛行率不斷上升以及標靶治療研發投資不斷增加的影響。此外，生物資訊學和基因組學的技術進步透過實現更精確的藥物設計而增加了市場潛力。目前的機會在於擴大 FDA核准的現有 HDAC 抑制劑治療多發性骨髓瘤和其他癌症的適應症，以及探索與免疫腫瘤治療的聯合治療。抗藥性、副作用和表觀遺傳調控的複雜性等挑戰，以及與臨床測試相關的高昂成本和時間表，構成了重大障礙。我們相信，技術創新的最佳方向是提高 HDAC 抑制劑的選擇性和治療指數，開發用於患者分層的生物標記，並整合人工智慧來最佳化藥物發現過程。 HDAC 抑制劑市場的競爭是溫和的，許多小型生物技術公司和大型製藥公司都希望取得進步，並且尋求擴大其產品組合和能力的公司有明顯的整合和聯盟趨勢。公司可能會發現策略聯盟的價值，以加速開發並引入有前途的先導化合物，以在這個充滿活力的領域中保持競爭力。

主要市場統計
基準年[2023] 164.3億美元
預測年份 [2024] 183.2億美元
預測年份 [2030] 362.5億美元
複合年成長率（%） 11.96%

市場動態：揭示快速發展的組蛋白去乙醯化酶抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變組蛋白去乙醯化酶抑制劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 癌症發生率增加，需要有效的治療方法
    • 在慢性病的預後、治療和診斷的應用不斷增加
    • 由於其穩定情緒和抗癲癇的特性，精神病學和神經科。
  • 市場限制因素
    • 人才意識淡薄，報銷政策缺失
    • 原料高成本且缺乏訓練有素的專業人員
  • 市場機會
    • 採用先進技術並加強製造商和公司之間的合作
    • 政府和私人組織增加對藥物開發的投資
  • 市場問題
    • 關於製造和潛在副作用（例如毒性）的嚴格規定

波特五力：駕馭組蛋白去乙醯化酶抑制劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解對組蛋白去乙醯化酶抑制劑市場的外部影響

外部宏觀環境因素在塑造組蛋白去乙醯化酶抑制劑市場的績效動態發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解組蛋白去乙醯化酶抑制劑市場的競爭格局

對組蛋白去乙醯化酶抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：組蛋白去乙醯化酶抑制劑市場供應商的績效評估

FPNV定位矩陣是評估組蛋白去乙醯化酶抑制劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製組蛋白去乙醯化酶抑制劑市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對組蛋白去乙醯化酶抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加以及有效治療方法的需求
      • 在慢性病的預後、治療和診斷的應用不斷增加
      • 由於其穩定情緒和抗癲癇的特性，精神病學和神經科的需求正在增加。
    • 抑制因素
      • 人力資源意識缺乏，薪酬政策缺失
      • 原料高成本且缺乏訓練有素的專業人員
    • 機會
      • 引進先進技術並擴大製造商和公司之間的合作
      • 政府和私人組織增加對藥物開發的投資
    • 任務
      • 關於製造和潛在副作用（例如毒性）的嚴格規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章組蛋白去乙醯化酶抑制劑市場：依類別

  • 介紹
  • I 類 HDAC
  • Ⅱ 類 HDAC
  • III 類 HDAC

第7章組蛋白去乙醯化酶抑制劑市場：依應用分類

  • 介紹
  • 中樞神經系統疾病
  • 神經病學
  • 腫瘤學

第8章北美和南美組蛋白去乙醯化酶抑制劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太組蛋白去乙醯化酶抑制劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲組蛋白去乙醯化酶抑制劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Celleron Therapeutics Ltd.
  • Eisai Co., Ltd.
  • Karyopharm Therapeutics Inc.
  • MEI Pharma Inc.
  • Merck KGaA
  • Midatech Pharma PLC
  • Novartis AG
  • Oncolys BioPharma Inc.
  • Regenacy Pharmaceuticals, Inc.
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Syndax Pharmaceuticals, Inc.
  • Tokyo Chemical Industry Co. , Ltd.
Product Code: MRR-437E9896A56B

The Histone Deacetylase Inhibitors Market was valued at USD 16.43 billion in 2023, expected to reach USD 18.32 billion in 2024, and is projected to grow at a CAGR of 11.96%, to USD 36.25 billion by 2030.

Histone deacetylase inhibitors (HDAC inhibitors) are a class of compounds that interfere with the function of histone deacetylases, enzymes implicated in modifying chromatin structure and regulating gene expression. Their primary necessity lies in oncology, where they are leveraged for their ability to induce apoptosis and cell cycle arrest in cancer cells. However, their application scope extends to neurological and inflammatory disorders, given their role in epigenetic modulation. The end-use scope primarily includes pharmaceutical companies focusing on novel cancer therapies and researchers exploring therapeutics for Alzheimer's and Huntington's diseases. Market growth for HDAC inhibitors is primarily influenced by an increasing prevalence of cancer and neurodegenerative disorders, coupled with heightened investment in research and development of targeted therapies. Additionally, technological advancements in bioinformatics and genomics bolster market potential by enabling more precise drug design. Current opportunities lie in expanding labels for existing FDA-approved HDAC inhibitors to treat multiple myeloma and other cancers, as well as exploring combination therapies alongside immuno-oncology agents. Challenges such as drug resistance, adverse effects, and the intricate nature of epigenetic regulation present significant hurdles, alongside the daunting costs and timelines associated with clinical trials. Innovation might best be directed toward improving the selectivity and therapeutic index of HDAC inhibitors, developing biomarkers for patient stratification, and integrating AI for optimizing drug discovery processes. The nature of the HDAC inhibitor market is moderately competitive with numerous small biotech firms and larger pharmaceutical companies striving for advancements, and a trend toward consolidation and collaboration evident as entities seek to expand their portfolios and capabilities. Businesses may find value in strategic alliances for accelerated development and in-lisencing promising lead compounds to stay competitive in this dynamic field.

KEY MARKET STATISTICS
Base Year [2023] USD 16.43 billion
Estimated Year [2024] USD 18.32 billion
Forecast Year [2030] USD 36.25 billion
CAGR (%) 11.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Histone Deacetylase Inhibitors Market

The Histone Deacetylase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of cancer coupled with need for effective treatment therapies
    • Increasing application in prognosis, treatment and diagnosis of chronic diseases
    • Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
  • Market Restraints
    • Dearth of awareness among people and lack of reimbursement policies
    • High cost of raw material and lack of trained professionals
  • Market Opportunities
    • Rising adoption of advanced technologies and collaboration among manufacturers and companies
    • Increasing investment for drug development from government and private organizations
  • Market Challenges
    • Strict mandates for the production and probable side effects such as toxicity

Porter's Five Forces: A Strategic Tool for Navigating the Histone Deacetylase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Histone Deacetylase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Histone Deacetylase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Histone Deacetylase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Histone Deacetylase Inhibitors Market

A detailed market share analysis in the Histone Deacetylase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Histone Deacetylase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Histone Deacetylase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Histone Deacetylase Inhibitors Market

A strategic analysis of the Histone Deacetylase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Histone Deacetylase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bristol Myers Squibb Company, Celleron Therapeutics Ltd., Eisai Co., Ltd., Karyopharm Therapeutics Inc., MEI Pharma Inc., Merck KGaA, Midatech Pharma PLC, Novartis AG, Oncolys BioPharma Inc., Regenacy Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Tokyo Chemical Industry Co. , Ltd..

Market Segmentation & Coverage

This research report categorizes the Histone Deacetylase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Class, market is studied across Class I HDACs, Class II HDACs, and Class III HDACs.
  • Based on Application, market is studied across Central Nervous System Disorders, Neurology, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of cancer coupled with need for effective treatment therapies
      • 5.1.1.2. Increasing application in prognosis, treatment and diagnosis of chronic diseases
      • 5.1.1.3. Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of awareness among people and lack of reimbursement policies
      • 5.1.2.2. High cost of raw material and lack of trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of advanced technologies and collaboration among manufacturers and companies
      • 5.1.3.2. Increasing investment for drug development from government and private organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Strict mandates for the production and probable side effects such as toxicity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Histone Deacetylase Inhibitors Market, by Class

  • 6.1. Introduction
  • 6.2. Class I HDACs
  • 6.3. Class II HDACs
  • 6.4. Class III HDACs

7. Histone Deacetylase Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Central Nervous System Disorders
  • 7.3. Neurology
  • 7.4. Oncology

8. Americas Histone Deacetylase Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Histone Deacetylase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Histone Deacetylase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bristol Myers Squibb Company
  • 3. Celleron Therapeutics Ltd.
  • 4. Eisai Co., Ltd.
  • 5. Karyopharm Therapeutics Inc.
  • 6. MEI Pharma Inc.
  • 7. Merck KGaA
  • 8. Midatech Pharma PLC
  • 9. Novartis AG
  • 10. Oncolys BioPharma Inc.
  • 11. Regenacy Pharmaceuticals, Inc.
  • 12. Shenzhen Chipscreen Biosciences Co., Ltd.
  • 13. Spectrum Pharmaceuticals, Inc.
  • 14. Syndax Pharmaceuticals, Inc.
  • 15. Tokyo Chemical Industry Co. , Ltd.

LIST OF FIGURES

  • FIGURE 1. HISTONE DEACETYLASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HISTONE DEACETYLASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023